Systematic Review and Network Meta-Analysis of SGLT2 Inhibitors for Type 2 Diabetes

Shan Gao authored a systematic review and network meta-analysis comparing the effectiveness and safety of bexagliflozin against other SGLT2 inhibitors for type 2 diabetes. The analysis includes 48 randomized controlled trials with 26,838 patients, sourced from PubMed, Embase, Web of Science, and ClinicalTrials.gov up to January 2026. The document was last updated on 2026-05-13.

Use Cases

• Comparing HbA1c reduction efficacy among different SGLT2 inhibitors based on the network meta-analysis results.
• Evaluating the safety profile of bexagliflozin relative to other agents based on urinary tract infection incidence data.
• Ranking SGLT2 inhibitors for weight loss and blood pressure control based on the reported surface under the cumulative ranking curve (SUCRA) values.

Strengths

• Analysis includes 48 randomized controlled trials with 26,838 patients, providing a substantial evidence base.
• Risk of bias was assessed using the Cochrane tool and evidence certainty evaluated with the CINeMA approach.
• The study compares multiple SGLT2 inhibitors across several efficacy and safety endpoints, including HbA1c, fasting plasma glucose, body weight, and blood pressure.

Limitations

• The dataset is a 1.3 MB DOCX document; the underlying structured data (e.g., trial-level data) is not directly accessible.
• Column-level documentation and sample data are unavailable, requiring manual extraction from the text report.
• Row count for any underlying data tables is unknown, limiting suitability assessment for direct computational analysis.

Provenance

Source

figshare

Collection Method

Systematic review and network meta-analysis of randomized controlled trials.

Time Range

Trials published up to January 2026.

Freshness

Last updated 2026-05-13 04:52:04.